1-2 of 2
Jay K. Wasman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin

Beth Overmoyer, Pingfu Fu, Charles Hoppel, Tomas Radivoyevitch, Robert Shenk, Marjie Persons, Paula Silverman, Kelly Robertson, Nicholas P. Ziats, Jay K. Wasman, Fadi W. Abdul-Karim, John A. Jesberger, Jeffrey Duerk, Paul Hartman, Shelli Hanks, Jonathan Lewin, Afshin Dowlati, Keith McCrae, Percy Ivy, Scot C. Remick
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5862–5868.
https://doi.org/10.1158/1078-0432.CCR-07-0688
Published: 01 October 2007
View article titled, Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin
Open the PDF for Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin in another window
Journal Articles

Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416

Afshin Dowlati, Kelly Robertson, Tomas Radivoyevitch, John Waas, Nicholas P. Ziats, Paul Hartman, Fadi W. Abdul-Karim, Jay K. Wasman, Jack Jesberger, Jonathan Lewin, Keith McCrae, Percy Ivy, Scot C. Remick
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7938–7944.
https://doi.org/10.1158/1078-0432.CCR-04-2538
Published: 08 November 2005
View article titled, Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416
Open the PDF for Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416 in another window